This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page  |  Contact Us  |  Report Abuse  |  Sign In  |  Register
News & Press: Clinical News

Lp(a) was a significant determinant of residual risk

Tuesday, February 11, 2014   (0 Comments)
Posted by: Sandra Tremulis
Share |

Circulation. 2013 Nov 17. [Epub ahead of print]

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial.

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S.
Author information
Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Abstract
BACKGROUND:

Lipoprotein(a) [Lp(a)] is an LDL-like particle largely independent of known risk factors and predictive of cardiovascular disease (CVD). Statins may offset the risk associated with elevated Lp(a), but it is unknown if Lp(a) is a determinant of residual risk in the setting of low LDL-cholesterol after potent statin therapy.METHODS AND RESULTS:

Baseline and on-treatment Lp(a) concentrations were assessed in 9,612 multiethnic JUPITER trial participants before and after random allocation to rosuvastatin 20 mg/day or placebo, with outcomes reported for whites (N=7,746). Lp(a) concentrations (nmol/L) were highest in blacks (median [25th-75th percentile] 60 [34-100]), then Asians (38 [18-60]), hispanics (24 [11-46]), and whites (23 [10-50]); p<0.001. While the median change in Lp(a) with rosuvastatin and placebo was zero, rosuvastatin nonetheless resulted in a small but statistically significant positive shift in the overall Lp(a) distribution (p<0.0001). Baseline Lp(a) concentrations were associated with incident CVD: adjusted hazard ratio (HR) per 1-SD increment in Ln[Lp(a)] 1.18 (95%CI 1.03 - 1.34; p=0.02). Similarly, on-statin Lp(a) concentrations were associated with residual risk of CVD: adjusted HR 1.27 (95%CI 1.01 - 1.59; p=0.04), which was independent of LDL-cholesterol and other factors. Rosuvastatin significantly reduced incident CVD among participants with baseline Lp(a)≥median (HR 0.62, 0.43-0.90) and Lp(a)

 

Among white JUPITER participants treated with potent statin therapy, Lp(a) was a significant determinant of residual risk. The magnitude of relative risk reduction with rosuvastatin was similar among participants with high or low Lp(a).CLINICAL TRIALS REGISTRATION INFORMATION:

clinicaltrial.gov. Identifier: NCT00239681.


Community Search
Sign In
Login with LinkedIn
OR


Latest News
 
809 Laurel Street #460
San Carlos, CA 94070
650/995.3242